ESTA
Establishment Labs Holdings Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
73.35
P/S
8.10
EV/EBITDA
-75.29
DCF Value
$-86.43
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
69.3%
Operating Margin
-18.5%
Net Margin
-24.2%
ROE
-201.8%
ROA
-14.8%
ROIC
-11.9%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $64.6M | $-2.6M | $-0.09 |
| FY 2025 | $211.1M | $-51.1M | $-1.72 |
| Q3 2025 | $53.8M | $-11.1M | $-0.38 |
| Q2 2025 | $51.3M | $-16.6M | $-0.56 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
CR
Exchange
NASDAQ
Beta
1.08
Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand name. It also provides Motiva Ergonomix and Motiva Ergonomix2 gravity sensitive round soft silicone-gel-filled breast implants; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.